Other causes of resistance to EGFR TKIs include amplification of MET gene (approximately 20% of patients), small cell or squamous cell lung cancer transformation, loss of the primary EGFR gene mutation, secondary mutations in KRAS or PIK3CA genes, and the occurrence of disorders in ALK gene [3]. This evidence concerns the gene EGFR and squamous cell lung carcinoma.